- Clinical Research Organisation
Affinity is a privately-owned biotechnology company based in Melbourne, Australia.
Founded by biotechnology entrepreneurs Ben Kiefel and Matt Beasley in 2009, Affinity started to build and develop the world’s fastest antibody discovery platform.
Affinity’s resulting technology, Retained DisplayTM (ReD), has since been tested in campaigns against some of the most difficult diagnostic and lab reagent targets the team could find.
